Cardiac Assessment With Atrial Fibrillation and Closing Thoughts

The panelists discuss how a beta blocker for atrial fibrillation affects baseline cardiac assessment, stressing the QTcF and frequent EKGs when starting revumenib. In closing remarks, one panelist says a practice new to menin inhibitors needs reliable EKG and lab monitoring and patient education on differentiation syndrome. Another expects differentiation syndrome management to eventually become routine, as it did with IDH inhibitors. The program ends with the panelists naming a question they want answered. The moderator closes the program.